Anti-PLA2R-associated membranous nephropathy: a review with emphasis on diagnostic testing methods

Area of Science:

• Nephrology
• Immunology
• Pathology

Background:

• Primary membranous nephropathy (MN) frequently involves autoantibodies against the podocyte antigen M-type phospholipase A2 receptor (PLA2R).
• Diagnosis relies on detecting anti-PLA2R in serum or PLA2R antigen in kidney biopsies.
• PLA2R testing is increasingly used in clinical practice for MN management.

Purpose of the Study:

• To review current methods for PLA2R testing in MN.
• To highlight unique aspects of anti-PLA2R-associated MN.
• To address ongoing questions regarding PLA2R testing in secondary MN and PLA2R-negative primary MN.

Main Methods:

• Literature review of studies on PLA2R testing in membranous nephropathy.
• Analysis of diagnostic approaches including serum antibody detection and kidney biopsy immunofluorescence.
• Discussion of clinical implications and unresolved issues in PLA2R testing.

Main Results:

• Anti-PLA2R autoantibodies are a hallmark of most primary MN cases.
• PLA2R testing aids in diagnosis, prognosis, and monitoring treatment response in MN.
• Existing literature provides a foundation for understanding PLA2R's role, but further research is needed for complex cases.

Conclusions:

• PLA2R testing is a valuable tool in the diagnosis and management of primary membranous nephropathy.
• Further research is required to clarify the role of PLA2R testing in secondary MN and PLA2R-negative MN.
• Standardization and interpretation of PLA2R testing continue to evolve in clinical nephrology.